Bazedoxifene – A New Selective Estrogen Receptor Modulator Treatment for Men with Schizophrenia: a double-blind, randomized, placebo controlled trial

Monash University Foundation0 个研究点目标入组 100 人开始时间: 2019年10月23日最近更新: 2019年10月28日

适应症

试验速览

暂无简介。

•Physically well.
•A current DSM-V diagnosis of schizophrenia or related disorder.
•18- 65 years
•Able to give informed consent.
•PANSS total score between 40 and 90 and a score of 4 (moderate) or more on two or more of the following PANSS items: delusions, hallucinatory behaviour, conceptual disorganization or suspiciousness.
•Stable psychotropic medication for previous 4 weeks
•IQ > 70 (as determined by the WAIS IV subtests)
•English language proficiency (in order to provide informed consent and complete cognitive test battery)

•Patients with known abnormalities in the hypothalamo-pituitary gonadal axis, thyroid dysfunction, central nervous system tumours, active or past history of a venous thromboembolic event.
•Patients with a history of severe traumatic brain injury or significant neurological or unstable medical illness such as epilepsy and diabetes or known active cardiac, renal or liver disease; presence of illness causing immobilisation.
•Patients whose psychotic illness is directly related to illicit substance use or who have a history of substance dependence during the last six months (with the exclusion of caffeine and/or nicotine dependence).
•Use of any form of estrogen, progestin or androgen as hormonal therapy in preceding 4 weeks including the pill.
•Planned changes to psychotropic medication or psychotherapy regimen.

发起方

Monash University Foundation